IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Novartis Phase 3 Pelacarsen Trial Misses Cardiovascular Endpoint — Sep 5, 2026Novartis reported that the Phase III Lp(a)HORIZON trial did not meet its primary endpoint, showing that lowering Lp(a) with pelacarsen reduced levels but did not significantly reduce cardiovascular events in approximately 8,000 patients on guideline-directed therapy; the company said full data will be presented at a future medical congress. Meanwhile, Royalty Pharma outlined its financial stance on the pelacarsen investment, noting the trial’s failure won’t derail its recovery of invested funds and that royalties on Spinraza remain a key part of its portfolio as it pursues its 2030 receipts target, with Ionis royalties potentially reverting after a defined cap. The developments reflect a broader scientific and market reevaluation of Lp(a)-targeted therapies and their commercial prospects.

Jared Kim Wonder how many other Lp(a) drugs in the pipeline just got a lot riskier to fund after this readout.

Hanmi Genentech obesity drug deal worth $2.3B reported — Aug 24, 2026Hanmi Pharmaceutical has signed an exclusive, worldwide license with Genentech for HM17321, a long-acting UCN2 analog aimed at obesity that promises weight loss with muscle preservation, with Genentech taking over development from Phase 2 onward outside Korea. The deal could reach about $2.3 billion, including a $190 million upfront, up to $2.1 billion in milestones, and future royalties, subject to U.S. antitrust clearance and successful clinical progression.